Inhibikase Therapeutics(US:IKT)2022-08-17 22:41Pipeline and Programs - Inhibikase Therapeutics is developing a multi-therapeutic pipeline of kinase inhibitor therapeutics focused on neurodegeneration, oncology, and infectious diseases[3] - IkT-148009, a lead c-Abl inhibitor program, is in Phase 2a study for Parkinson's disease (PD) and related disorders[4] - IkT-001Pro, an oncology product, is a BCR-Abl inhibitor with a potentially improved safety profile for leukemias and gastrointestinal cancers, with an IND application submitted for Chronic Myeloid Leukemia[5] - The company has a robust patent portfolio with protection to 2033 for oncology and 2036 for neurodegeneration[5] Financial Highlights - The company received $20.8 million in peer-reviewed grants and contracts from NIH, DoD, the Michael J Fox Foundation, and the Georgia Research Alliance[6] - Inhibikase Therapeutics secured $63 million in gross proceeds from investor capital in 2021[6] - As of June 30, 2022, the company's total working capital was $29,773,286[41] - As of June 30, 2022, the company's cash holdings were $32,212,276[43] Market and Clinical Data - The U S Parkinson's disease market is large, with an estimated 930,000 to 1,200,000 patients[11] - By 2025, Parkinson's disease drug sales are expected to exceed $6 billion[11] - Phase 1 trial data for IkT-148009 showed dose-proportional clinical pharmacokinetics and no clinically significant adverse events in healthy subjects (N=88) and Parkinson's patients (N=13)[24] - In CML, Gleevec® and its generics have $330.5 million in net U S sales, with generic Gleevec® holding over 57% market share[33]